Company: MIRM
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001759425-25-000032
Chunk: 342

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 342
---
 and other current liabilities or in other liabilities on the accompanying unaudited condensed consolidated balance sheets depending on contractual settlement timelines.The following table represents total revenues and disaggregates Product sales, net by approved medicine (in thousands): Three Months Ended March 31, 20252024Product sales, net:  Livmarli$73,224 $42,845 Bile Acid Medicines38,361 26,072 Total product sales, net111,585 68,917 License and other revenue— 305 Total revenues$111,585 $69,222 The following table sets forth Product sales, net by geographic area based on the ship-to location (in thousands): Three Months Ended March 31, 20252024United States$86,922 $56,111 Rest of the world24,663 12,806 Total product sales, net$111,585 $68,917 Foreign CurrencyThe unaudited condensed consolidated financial statements are presented in U.S. dollars. The functional currency for most of the Company’s foreign subsidiaries is their local currency. Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period. Income statement items are 

9

translated at average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity.Foreign currency transaction gains and losses are included in other income (expense), net in the unaudited condensed consolidated statements of operations. Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction. Unrealized foreign exchange gains amounted to $0.7 million and $1.7 million for the three months ended March 31, 2025 and 2024, respectively. Realized foreign exchange gains and losses were insignificant for the three months ended March 31, 2025 and 2024.Net Loss Per ShareBasic net loss per share is computed by dividing net loss by the weighted-average shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. Diluted net loss per share excludes the potential impact of the Company’s common stock subject to repurchase, common stock options, restricted